Rhythm Pharmaceuticals (NASDAQ: RYTM) releases Q3 2025 results

Rhea-AI Filing Summary

Rhythm Pharmaceuticals, Inc. filed a current report stating that on November 4, 2025 it announced financial results for the third quarter ended September 30, 2025. The company released these results through a press release, which is provided as Exhibit 99.1.

The press release is being furnished, not filed, meaning it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other securities law filings unless specifically referenced.

0001649904false00016499042025-11-042025-11-04

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

FORM 8-K

​

CURRENT REPORT

​

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): November 4, 2025

​

RHYTHM PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

​

Delaware		001-38223		46-2159271
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

​

222 Berkeley Street

12th Floor

Boston, MA 02116

(Address of principal executive offices) (Zip Code)

​

Registrant’s telephone number, including area code: (857) 264-4280

​

N/A

(Former name or former address, if changed since last report)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	RYTM	The Nasdaq Stock Market LLC (Nasdaq Global Market)

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

Item 2.02. Results of Operations and Financial Condition.

​

On November 4, 2025, Rhythm Pharmaceuticals, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2025. The full text of the press release issued by the Company in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Current Report”).

​

The information contained in Item 2.02 of this Current Report (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly provided by specific reference in such a filing.

​

​

​

Item 9.01. Financial Statements and Exhibits.

​

(d) Exhibits

​

The following Exhibit 99.1 relates to Item 2.02 and shall be deemed to be furnished, and not filed:

​

Exhibit No.		Description
99.1		Press release dated November 4, 2025
104		Cover Page Interactive Data File (embedded within the inline XBRL document)

​

​

​

SIGNATURES

​

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

	RHYTHM PHARMACEUTICALS, INC.
Date: November 4, 2025	By:	/s/ Hunter C. Smith
		Hunter C. Smith
		Chief Financial Officer

​

​

​

FAQ

What did Rhythm Pharmaceuticals (RYTM) report on November 4, 2025?

On November 4, 2025, Rhythm Pharmaceuticals, Inc. announced its financial results for the third quarter ended September 30, 2025 and described this in a current report.

How did Rhythm Pharmaceuticals disclose its Q3 2025 financial results?

The company disclosed its Q3 2025 financial results in a press release that is attached to the report as Exhibit 99.1.

Is the Rhythm Pharmaceuticals Q3 2025 press release considered filed with the SEC?

No. The Q3 2025 press release is furnished, not filed, so it is not subject to Section 18 liability of the Exchange Act and is not automatically incorporated into other filings.

Which period do the reported financial results for Rhythm Pharmaceuticals cover?

The reported financial results cover the third quarter ended September 30, 2025.

Which exhibit contains Rhythm Pharmaceuticals’ Q3 2025 earnings press release?

The Q3 2025 earnings press release is included as Exhibit 99.1 to the report.

Who signed the Rhythm Pharmaceuticals current report about Q3 2025 results?

The report was signed on behalf of Rhythm Pharmaceuticals, Inc. by Hunter C. Smith, the company’s Chief Financial Officer.